Physician profile
Constantine George
NPI 1164429858
$1,205.37
in general payments reported to CMS, 2019-2025
30 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $130 · 2022: $71.64 · 2023: $107 · 2024: $284 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $204.74 | 2019-2025 | Xyosted |
| Abbvie INC. | $165.91 | 2020-2025 | |
| Gilead Sciences, INC. | $79.68 | 2020-2025 | |
| Novo Nordisk INC | $67.60 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $64.69 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Aytu Biopharma, INC. | $49.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $42.66 | 2022-2024 | |
| Pfizer INC. | $41.07 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $38.22 | 2023-2025 | Farxiga, Airsupra |
| Ibsa Pharma INC. | $36.48 | 2020-2023 | Tirosint, Licart |
| Cranial Technologies, INC | $34.96 | 2024-2025 | Doc Band |
| Viiv Healthcare Company | $33.80 | 2024 | Apretude |
| Boston Scientific Corporation | $29.46 | 2019 | |
| Lilly USA, LLC | $25.71 | 2022-2025 | Mounjaro, Zepbound |
| Ucb, INC. | $25.42 | 2024 | Briviact |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $24.92 | 2019 | |
| Amgen INC. | $23.52 | 2024 | Repatha |
| Impel Pharmaceuticals INC. | $21.56 | 2022 | |
| Ethicon US, LLC | $19.36 | 2019 | |
| Exact Sciences Corporation | $18.98 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $18.64 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $17.90 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.39 | 2020 | |
| Merck Sharp & Dohme LLC | $17.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2019 | |
| Genentech USA, INC. | $14.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.30 | 2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $14.20 | 2020 | |
| Upsher-Smith Laboratories LLC | $13.76 | 2020 | |
| Tolmar, INC. | $13.71 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.